Keurig Dr Pepper vs Johnson & Johnson
Side-by-side comparison of AI visibility scores, market position, and capabilities
Burlington MA beverages (NASDAQ: KDP) at $15.35B FY2024 revenue (+3.6%); Dr Pepper/7UP/Snapple + Keurig K-Cup, 82% FCF growth, 2025 guidance mid-single-digit growth competing with Coca-Cola and PepsiCo.
About
Keurig Dr Pepper Inc. is a Burlington, Massachusetts-based beverage company — publicly traded on NASDAQ (NASDAQ: KDP) as an S&P 500 Consumer Staples component — manufacturing, marketing, and distributing hot beverages (coffee through the Keurig single-serve system and Green Mountain roasted coffee brands), cold beverages (Dr Pepper, 7UP, Snapple, Canada Dry, A&W, Sunkist, Bai, Core, Clamato, Mott's, Hawaiian Punch, Penafiel), and producing/selling the Keurig K-Cup system (over 500 varieties of licensed K-Cup pods from 75+ coffee brands) through approximately 27,000 employees. In fiscal year 2024, Keurig Dr Pepper reported revenue of $15.35 billion (+3.6% year-over-year), adjusted diluted EPS growth of 8%, operating cash flow growth of 67% to $2.2 billion, and free cash flow growth of 82% to $1.7 billion. For 2025, KDP guided mid-single-digit net sales growth and high-single-digit adjusted EPS growth, reflecting continued volume growth in both the cold beverages portfolio and Keurig brewer and pod sales recovery. CEO Tim Cofer, who joined from Mondelez International in 2023, has prioritized revenue management (balancing price and volume), operational efficiency, and brand investment across KDP's portfolio of over 125 owned, licensed, and partner brands. Keurig Dr Pepper was formed through the 2018 merger of Keurig Green Mountain (coffee systems) and Dr Pepper Snapple Group (beverages), controlled by JAB Holding Company (a Luxembourg-based holding company of the Reimann family).
FY2024 Sales: $88.8B (+4.3%) | Net Profit: $14.1B (+5.6%) | EPS: $5.79 | Adjusted EPS: $9.98 | FY2025 Guidance: Operational Sales Growth 2.5-3.5%, Adj EPS $10.75-$10.95 (+8.7% midpoint)
About
Johnson & Johnson is one of the world's largest healthcare companies, founded in 1886 by brothers Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson in New Brunswick, New Jersey, where the company remains headquartered. Established to manufacture ready-to-use surgical dressings at a time when post-operative infection was a leading cause of surgical mortality, J&J was built on the scientific principles of antiseptic surgery advocated by Joseph Lister. The company trades on the NYSE under ticker JNJ and has evolved over 135+ years from a consumer health products manufacturer into a focused MedTech and pharmaceutical enterprise, completing the spinoff of its consumer health segment (Kenvue) in 2023.\n\nJohnson & Johnson now operates through two segments: Innovative Medicine and MedTech. Innovative Medicine encompasses oncology, immunology, neuroscience, infectious disease, and cardiovascular pharmaceutical products — including blockbusters Darzalex, Stelara, Tremfya, and Rybrevant. The MedTech segment includes surgical robotics (Ottava platform in development), electrophysiology (Abiomed, Biosense Webster), orthopedics (DePuy Synthes), and surgery systems, serving hospitals and surgical centers worldwide. Following the Kenvue separation, J&J is a pure-play healthcare technology and pharmaceutical company with significantly higher growth and margin profiles than its historical blended consumer-pharma-medtech structure.\n\nJohnson & Johnson reported FY2024 sales of $88.8 billion, up 4.3% year over year, with net profit of $14.1 billion, up 5.6%. The company's Innovative Medicine segment continues to grow driven by oncology and immunology portfolio strength, while MedTech benefits from procedure volume recovery and robotic surgery adoption. J&J's scale, R&D pipeline depth, and global commercial infrastructure — spanning more than 60 countries — position it as one of the two or three most consequential healthcare enterprises globally, with a patent portfolio, clinical trial network, and regulatory expertise that are nearly impossible to replicate.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.